327 related articles for article (PubMed ID: 27733075)
21. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
Russo F; Corazzelli G; Frigeri F; Capobianco G; Aloj L; Volzone F; De Chiara A; Bonelli A; Gatani T; Marcacci G; Donnarumma D; Becchimanzi C; de Lutio E; Ionna F; De Filippi R; Lastoria S; Pinto A
Br J Haematol; 2014 Jul; 166(1):118-29. PubMed ID: 24673727
[TBL] [Abstract][Full Text] [Related]
22. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
23. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
24. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of CD7 in classical Hodgkin lymphoma-infiltrating T lymphocytes.
Seegmiller AC; Karandikar NJ; Kroft SH; McKenna RW; Xu Y
Cytometry B Clin Cytom; 2009 May; 76(3):169-74. PubMed ID: 18956470
[TBL] [Abstract][Full Text] [Related]
26. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
27. Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy.
Fernandez-Alvarez R; Gonzalez-Rodriguez AP; Gonzalez ME; Rubio-Castro A; Dominguez-Iglesias F; Solano J; Alonso-Nogues E; Fernandez-Alvarez C; Zanabili Y; Alonso JM; Payer AR; Vicente JM; Medina J; Sancho JM
Leuk Lymphoma; 2015; 56(11):3096-102. PubMed ID: 25860241
[TBL] [Abstract][Full Text] [Related]
28. T-cell levels are prognostic in mantle cell lymphoma.
Nygren L; Wasik AM; Baumgartner-Wennerholm S; Jeppsson-Ahlberg Å; Klimkowska M; Andersson P; Buhrkuhl D; Christensson B; Kimby E; Wahlin BE; Sander B
Clin Cancer Res; 2014 Dec; 20(23):6096-104. PubMed ID: 25294911
[TBL] [Abstract][Full Text] [Related]
29. Early intensification treatment approach in advanced-stage Hodgkin lymphoma.
Borchmann P
Hematol Oncol Clin North Am; 2014 Feb; 28(1):65-74. PubMed ID: 24287068
[TBL] [Abstract][Full Text] [Related]
30. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Engert A; Plütschow A; Eich HT; Lohri A; Dörken B; Borchmann P; Berger B; Greil R; Willborn KC; Wilhelm M; Debus J; Eble MJ; Sökler M; Ho A; Rank A; Ganser A; Trümper L; Bokemeyer C; Kirchner H; Schubert J; Král Z; Fuchs M; Müller-Hermelink HK; Müller RP; Diehl V
N Engl J Med; 2010 Aug; 363(7):640-52. PubMed ID: 20818855
[TBL] [Abstract][Full Text] [Related]
31. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
[TBL] [Abstract][Full Text] [Related]
32. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.
Böll B; Görgen H; Fuchs M; Pluetschow A; Eich HT; Bargetzi MJ; Weidmann E; Junghanß C; Greil R; Scherpe A; Schmalz O; Eichenauer DA; von Tresckow B; Rothe A; Diehl V; Engert A; Borchmann P
J Clin Oncol; 2013 Apr; 31(12):1522-9. PubMed ID: 23509310
[TBL] [Abstract][Full Text] [Related]
33. ABVD-Based Therapy for Hodgkin Lymphoma in Children and Adolescents: Lessons Learnt in a Tertiary Care Oncology Center in a Developing Country.
Jain S; Kapoor G; Bajpai R
Pediatr Blood Cancer; 2016 Jun; 63(6):1024-30. PubMed ID: 26855007
[TBL] [Abstract][Full Text] [Related]
34. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
[TBL] [Abstract][Full Text] [Related]
35. Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
[TBL] [Abstract][Full Text] [Related]
36. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
[TBL] [Abstract][Full Text] [Related]
37. Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma.
Guidetti A; Mazzocchi A; Miceli R; Paterno' E; Taverna F; Spina F; Crippa F; Farina L; Corradini P; Gianni AM; Viviani S
Leuk Res; 2017 Nov; 62():91-97. PubMed ID: 28992524
[TBL] [Abstract][Full Text] [Related]
38. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
39. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
[TBL] [Abstract][Full Text] [Related]
40. Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.
Mikkilineni L; Whitaker-Menezes D; Domingo-Vidal M; Sprandio J; Avena P; Cotzia P; Dulau-Florea A; Gong J; Uppal G; Zhan T; Leiby B; Lin Z; Pro B; Sotgia F; Lisanti MP; Martinez-Outschoorn U
Semin Oncol; 2017 Jun; 44(3):218-225. PubMed ID: 29248133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]